Q4 Earnings Forecast for Insulet Issued By Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share estimates for Insulet in a report released on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will earn $0.99 per share for the quarter, down from their previous forecast of $1.00. The consensus estimate for Insulet’s current full-year earnings is $3.10 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.22 EPS, FY2027 earnings at $6.46 EPS and FY2028 earnings at $7.75 EPS.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday. Citigroup increased their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Canaccord Genuity Group increased their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday. Finally, Barclays increased their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Shares of PODD stock opened at $275.70 on Monday. Insulet has a 12-month low of $156.00 and a 12-month high of $279.40. The firm has a market capitalization of $19.33 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. The business has a 50 day simple moving average of $233.46 and a 200 day simple moving average of $205.26. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71.

Institutional Trading of Insulet

Institutional investors have recently bought and sold shares of the business. Blue Trust Inc. lifted its position in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Insulet during the 2nd quarter worth about $32,000. Venturi Wealth Management LLC grew its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. grew its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the last quarter. Finally, CVA Family Office LLC grew its stake in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.